Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy-Reference-Cited by-同舟云学术

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

Published:2009-09-16 Issue:5 Volume:11 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Darb-Esfahani Silvia,Loibl Sibylle,Müller Berit M,Roller Marc,Denkert Carsten,Komor Martina,Schlüns Karsten,Blohmer Jens Uwe,Budczies Jan,Gerber Bernd,Noske Aurelia,du Bois Andreas,Weichert Wilko,Jackisch Christian,Dietel Manfred,Richter Klaus,Kaufmann Manfred,von Minckwitz Gunter

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr2363.pdf

Reference43 articles.

1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007, 18: 1133-44. 10.1093/annonc/mdm271.

2. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, Lebeau A, Loibl S, Miller W, Seeber S, Semiglazov V, Smith R, Souchon R, Stearns V, Untch M, von Minckwitz G: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006, 24: 1940-9. 10.1200/JCO.2005.02.6187.

3. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997, 15: 2483-93.

4. Fisher B, Bryant J, Wolmark NE, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998, 16: 2672-85.

5. Scholl SM, Pierga JY, Asselain B, Beuzeboc P, Dorval T, Garcia-Giralt E, Jouve M, Palangié T, Remvikos Y, Durand JC: Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995, 31A: 1969-75. 10.1016/0959-8049(95)00454-8.

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple‐negative breast cancer (TNBC);Drug Development Research;2023-04-05

2. Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics;Cell Death Discovery;2023-02-09

3. Neoadjuvant treatment and survival outcomes by pathologic complete response in HER2-negative early breast cancers;Future Oncology;2023-01

4. Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer;Journal of Controlled Release;2022-02

5. YB1 Is a Major Contributor to Health Disparities in Triple Negative Breast Cancer;Cancers;2021-12-14